Literature DB >> 24291785

Therapeutic perspectives of Eph-ephrin system modulation.

Massimiliano Tognolini1, Iftiin Hassan-Mohamed2, Carmine Giorgio2, Ilaria Zanotti2, Alessio Lodola2.   

Abstract

Eph receptors are the largest class of kinase receptors and, together with their ligands ephrins, they have a primary role in embryogenesis. Their expression has been found deregulated in several cancer tissues and, in many cases, abnormal levels of these proteins have been correlated to a poor prognosis. Recently, the Eph-ephrin system was found to be deregulated in other pathological processes, involving the nervous and cardiovascular systems. The increasing body of evidence supports the Eph-ephrin system as a target not only for the treatment of solid tumors, but also to face other critical diseases such as amyotrophic lateral sclerosis and diabetes driving current efforts toward the development of pharmacological tools potentially able to treat these pathologies.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24291785     DOI: 10.1016/j.drudis.2013.11.017

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

1.  Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors:  Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

Review 2.  Eph receptors and ephrins: therapeutic opportunities.

Authors:  Antonio Barquilla; Elena B Pasquale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-03       Impact factor: 13.820

3.  Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.

Authors:  Erika J Olson; Bernhard C Lechtenberg; Chunxia Zhao; Elena Rubio de la Torre; Ilaria Lamberto; Stefan J Riedl; Philip E Dawson; Elena B Pasquale
Journal:  ACS Med Chem Lett       Date:  2016-06-25       Impact factor: 4.345

4.  UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.

Authors:  I Hassan-Mohamed; C Giorgio; M Incerti; S Russo; D Pala; E B Pasquale; I Zanotti; P Vicini; E Barocelli; S Rivara; M Mor; A Lodola; M Tognolini
Journal:  Br J Pharmacol       Date:  2014-08-28       Impact factor: 8.739

Review 5.  The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases.

Authors:  Radoslaw Kaczmarek; Katarzyna Zimmer; Pawel Gajdzis; Malgorzata Gajdzis
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

6.  A mathematical model for eph/ephrin-directed segregation of intermingled cells.

Authors:  Rotem Aharon; Peter W Janes; Anthony W Burgess; Kais Hamza; Fima Klebaner; Martin Lackmann
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

7.  Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.

Authors:  Ilaria Lamberto; Bernhard C Lechtenberg; Erika J Olson; Peter D Mace; Philip E Dawson; Stefan J Riedl; Elena B Pasquale
Journal:  ACS Chem Biol       Date:  2014-10-14       Impact factor: 5.100

8.  Identification and characterization of Nanobodies targeting the EphA4 receptor.

Authors:  Lies Schoonaert; Laura Rué; Bart Roucourt; Mieke Timmers; Susan Little; Lucía Chávez-Gutiérrez; Maarten Dewilde; Peter Joyce; Adam Curnock; Peter Weber; Jurgen Haustraete; Gholamreza Hassanzadeh-Ghassabeh; Bart De Strooper; Ludo Van Den Bosch; Philip Van Damme; Robin Lemmens; Wim Robberecht
Journal:  J Biol Chem       Date:  2017-05-19       Impact factor: 5.157

Review 9.  The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.

Authors:  Enming Du; Xue Li; Siyu He; Xiaohua Li; Shikun He
Journal:  Mol Biol Rep       Date:  2020-06-02       Impact factor: 2.316

10.  Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.

Authors:  Bridget A Quinn; Si Wang; Elisa Barile; Swadesh K Das; Luni Emdad; Devanand Sarkar; Surya K De; Susan Kharagh Morvaridi; John L Stebbins; Stephen J Pandol; Paul B Fisher; Maurizio Pellecchia
Journal:  Oncotarget       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.